Published in Mol Cell Ther on March 26, 2014
Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection | NCT01734850
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med (2013) 10.63
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med (2014) 7.64
Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med (2013) 6.63
HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med (2011) 6.30
Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity (2012) 6.29
Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog (2013) 6.14
Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity (2013) 4.82
Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med (2012) 3.29
Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog (2013) 2.44
An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog (2013) 2.16
Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev (2014) 1.86
Vaccine-induced CD8+ T cells control AIDS virus replication. Nature (2012) 1.78
Potent inhibition of HIV-1 by TRIM5-cyclophilin fusion proteins engineered from human components. J Clin Invest (2009) 1.73
Homeostatic proliferation fails to efficiently reactivate HIV-1 latently infected central memory CD4+ T cells. PLoS Pathog (2011) 1.64
Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discov Today (2012) 1.47
Targeted cytotoxic therapy kills persisting HIV infected cells during ART. PLoS Pathog (2014) 1.32
Ending AIDS--is an HIV vaccine necessary? N Engl J Med (2014) 1.27
Positive selection of mC46-expressing CD4+ T cells and maintenance of virus specific immunity in a primate AIDS model. Blood (2013) 1.13
Altering cell death pathways as an approach to cure HIV infection. Cell Death Dis (2013) 0.99
Genetically modified hematopoietic stem cell transplantation for HIV-1-infected patients: can we achieve a cure? Mol Ther (2013) 0.95
Failure of short-term CD4-PE40 infusions to reduce virus load in human immunodeficiency virus-infected persons. J Infect Dis (1994) 0.90
Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells. Virology (2013) 0.88
Characterization of anti-HIV activity mediated by R88-APOBEC3G mutant fusion proteins in CD4+ T cells, peripheral blood mononuclear cells, and macrophages. Hum Gene Ther (2011) 0.82